title: Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.
abstract: Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP-specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure.
authors.affiliation: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada.
authors.forename: Xiangguo
authors.initials: X
authors.lastname: Qiu
authors.forename: Jonathan
authors.initials: J
authors.lastname: Audet
authors.forename: Gary
authors.initials: G
authors.lastname: Wong
authors.forename: Lisa
authors.initials: L
authors.lastname: Fernando
authors.forename: Alexander
authors.initials: A
authors.lastname: Bello
authors.forename: Stéphane
authors.initials: S
authors.lastname: Pillet
authors.forename: Judie B
authors.initials: JB
authors.lastname: Alimonti
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D029043:Ebolavirus / Q000276:immunology*; D005260:Female; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D007111:Immunity, Cellular / Q000276:immunology; D007156:Immunologic Memory / Q000276:immunology; D008252:Macaca fascicularis; D008297:Male; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016207:Cytokines; D014759:Viral Envelope Proteins; C113189:envelope glycoprotein, Ebola virus